These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16643518)

  • 21. [Low-level resistance to fluoroquinolones conferred by efflux overproduction in Pseudomonas aeruginosa: clinical significance and routine detection].
    Hocquet D; Patry I; Dupont P; Bize M; Jeannot K; Chavanet P; Plésiat P
    Pathol Biol (Paris); 2005; 53(8-9):495-9. PubMed ID: 16203109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Two efflux systems expressed simultaneously in clinical Pseudomonas aeruginosa].
    Hocquet D; Llanes C; Patry I; El Garch F; Plésiat P
    Pathol Biol (Paris); 2004 Oct; 52(8):455-61. PubMed ID: 15465264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
    Wolter DJ; Black JA; Lister PD; Hanson ND
    J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P; Widmer F; Middleton PG; Iredell J; George AM
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in the efflux pump regulator MexZ shift tissue colonization by Pseudomonas aeruginosa to a state of antibiotic tolerance.
    Laborda P; Lolle S; Hernando-Amado S; Alcalde-Rico M; Aanæs K; Martínez JL; Molin S; Johansen HK
    Nat Commun; 2024 Mar; 15(1):2584. PubMed ID: 38519499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
    Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
    Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
    Bretonnière C; Jacqueline C; Caillon J; Guitton C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
    J Antimicrob Chemother; 2010 Nov; 65(11):2423-7. PubMed ID: 20858688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of the MexXY multidrug efflux pump and other chromosomal mechanisms on aminoglycoside resistance in Pseudomonas aeruginosa isolates from canine and feline infections.
    Poonsuk K; Chuanchuen R
    J Vet Med Sci; 2012 Dec; 74(12):1575-82. PubMed ID: 22813987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats.
    Marier JF; Brazier JL; Lavigne J; Ducharme MP
    J Antimicrob Chemother; 2003 Aug; 52(2):247-52. PubMed ID: 12837733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
    MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
    J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa.
    Schurek KN; Marr AK; Taylor PK; Wiegand I; Semenec L; Khaira BK; Hancock RE
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4213-9. PubMed ID: 18824604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.
    Cai Y; Fan Y; Wang R; An MM; Liang BB
    J Antimicrob Chemother; 2009 Sep; 64(3):563-6. PubMed ID: 19561148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem potentiation of aminoglycoside activity against Pseudomonas aeruginosa: involvement of the MexXY-OprM multidrug efflux system.
    Poole K; Gilmour C; Farha MA; Parkins MD; Klinoski R; Brown ED
    J Antimicrob Chemother; 2018 May; 73(5):1247-1255. PubMed ID: 29420743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis.
    Reidy JJ; Hobden JA; Hill JM; Forman K; O'Callaghan RJ
    Cornea; 1991 Jan; 10(1):25-8. PubMed ID: 1902152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Islam S; Oh H; Jalal S; Karpati F; Ciofu O; Høiby N; Wretlind B
    Clin Microbiol Infect; 2009 Jan; 15(1):60-6. PubMed ID: 19154484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J
    Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.